Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

doi:10.1001/jamainternmed.2021.2209

. 2021 Sep 1;181(9):1241-1243.

doi: 10.1001/jamainternmed.2021.2209.

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette^{1

2}, Olivier Hermine^{3

4}, Pierre-Louis Tharaux⁵, Matthieu Resche-Rigon^{6

7}, Philippe Gabriel Steg^{8

9}, Raphaël Porcher¹⁰, Philippe Ravaud^{10

11}

Affiliations

¹ Department of Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
² Université Paris-Saclay, Institut national de la santé et de la recherche médicale (INSERM) UMR1184, Le Kremlin Bicêtre, Le Kremlin Bicêtre, France.
³ Department of Hematology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Institut Imagine, Université de Paris, INSERM UMR1183, Paris, France.
⁵ Paris Cardiovascular Center, Université de Paris, INSERM, F-75015 Paris, France.
⁶ Université de Paris, ECSTRRA Team, Centre of Research Epidemiology and Statistics, INSERM UMR1153, Paris, France.
⁷ URC Saint-Louis, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
⁸ Department of cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Université de Paris, INSERM U1148, Paris, France.
¹⁰ Université de Paris, Centre of Research Epidemiology and Statistics, INSERM U1153, Paris, France.
¹¹ Centre d'Epidémiologie Clinique, Assistance Publique des Hôpitaux de Paris, Hôpital Hôtel Dieu, Paris, France.

PMID: 34028504
PMCID: PMC8145157
DOI: 10.1001/jamainternmed.2021.2209

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Xavier Mariette et al. JAMA Intern Med. 2021.

. 2021 Sep 1;181(9):1241-1243.

doi: 10.1001/jamainternmed.2021.2209.

Authors

Xavier Mariette^{1

2}, Olivier Hermine^{3

4}, Pierre-Louis Tharaux⁵, Matthieu Resche-Rigon^{6

7}, Philippe Gabriel Steg^{8

9}, Raphaël Porcher¹⁰, Philippe Ravaud^{10

11}

Affiliations

¹ Department of Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
² Université Paris-Saclay, Institut national de la santé et de la recherche médicale (INSERM) UMR1184, Le Kremlin Bicêtre, Le Kremlin Bicêtre, France.
³ Department of Hematology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Institut Imagine, Université de Paris, INSERM UMR1183, Paris, France.
⁵ Paris Cardiovascular Center, Université de Paris, INSERM, F-75015 Paris, France.
⁶ Université de Paris, ECSTRRA Team, Centre of Research Epidemiology and Statistics, INSERM UMR1153, Paris, France.
⁷ URC Saint-Louis, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
⁸ Department of cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Université de Paris, INSERM U1148, Paris, France.
¹⁰ Université de Paris, Centre of Research Epidemiology and Statistics, INSERM U1153, Paris, France.
¹¹ Centre d'Epidémiologie Clinique, Assistance Publique des Hôpitaux de Paris, Hôpital Hôtel Dieu, Paris, France.

PMID: 34028504
PMCID: PMC8145157
DOI: 10.1001/jamainternmed.2021.2209

Abstract

This follow-up study of the CORIMUNO-TOCI-1 randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Steg reported personal fees from Amarin, Amgen, AstraZeneca, BMS, Idorsia, Novo Nordisk, Novartis, Pfizer, Sanofi, Servier, and Regeneron as well as grants from Bayer, Sanofi, Servier, and Amarin outside the submitted work. Dr Ravaud reported being a minority shareholder of INATO outside the submitted work. No other disclosures were reported.

Figures

See this image and copyright information in PMC

Cited by

Senescence as a therapeutic target in cancer and age-related diseases.
McHugh D, Durán I, Gil J. McHugh D, et al. Nat Rev Drug Discov. 2024 Nov 15. doi: 10.1038/s41573-024-01074-4. Online ahead of print. Nat Rev Drug Discov. 2024. PMID: 39548312 Review.
Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients.
Bruse N, Motos A, van Amstel R, de Bie E, Kooistra EJ, Jansen A, van Lier D, Kennedy J, Schwarzkopf D, Thomas-Rüddel D, Bermejo-Martin JF, Barbe F, de Keizer NF, Bauer M, van der Hoeven JG, Torres A, Seymour C, van Vught L, Pickkers P, Kox M. Bruse N, et al. Intensive Care Med. 2024 Nov;50(11):1884-1896. doi: 10.1007/s00134-024-07593-3. Epub 2024 Aug 26. Intensive Care Med. 2024. PMID: 39186112 Free PMC article.
COVID-19 Pneumonia and Cytokine Storm Syndrome.
van de Veerdonk FL. van de Veerdonk FL. Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22. Adv Exp Med Biol. 2024. PMID: 39117824 Review.
Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
Calderón-Ochoa C, Plamenov-Donchev N, Hernández-Quiñones F, Mendoza-López O, Hinojos-Gallardo LC, Longino-Gómez AJ, Hernádez-Saldaña R, Duque-Rodríguez J, Ishida-Gutiérrez MC. Calderón-Ochoa C, et al. Microbiol Spectr. 2024 Jun 4;12(6):e0249823. doi: 10.1128/spectrum.02498-23. Epub 2024 Apr 30. Microbiol Spectr. 2024. PMID: 38687065 Free PMC article.
The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study.
Başkol Elik D, Kaya Ş, Alkan S, Demirdal T, Sener A, Kaya S, Güzel Tunçcan Ö, Kayaaslan B, Güner R, Eser F, Kahraman H, Birengel S, Sarıcaoğlu EM, Eroğlu E, Çölkesen F, Öztürk E, Berk Cam H, Mermutluoğlu Ç, Özer Balin Ş, Sincan G, Altın N, Sili U, Suntur BM, Arslan Gülen T, Deveci B, Saba R, İncecik Ş, Eser Karlıdağ G, Hakko E, Akdağ D, Erdem HA, Sipahi H, Çicek C, Taşbakan MS, Taşbakan M, Pullukçu H, Yamazhan T, Arda B, Ulusoy S, Sipahi OR. Başkol Elik D, et al. Sci Rep. 2024 Mar 3;14(1):5218. doi: 10.1038/s41598-024-55886-w. Sci Rep. 2024. PMID: 38433274 Free PMC article.

See all "Cited by" articles

References

1. RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. Preprint posted February 11, 2021. doi:10.1101/2021.02.11.21249258 - DOI - PubMed
1. Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi:10.1056/NEJMoa2100433 - DOI - PMC - PubMed
1. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi:10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed
1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators . Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi:10.1056/NEJMoa2028836 - DOI - PMC - PubMed
1. Salvarani C, Dolci G, Massari M, et al. ; RCT-TCZ-COVID-19 Study Group . Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi:10.1001/jamainternmed.2020.6615 - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. Preprint posted February 11, 2021. doi:10.1101/2021.02.11.21249258 - DOI - PubMed

[2] RECOVERY Collaborative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. Preprint posted February 11, 2021. doi:10.1101/2021.02.11.21249258 - DOI - PubMed

[3] Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi:10.1056/NEJMoa2100433 - DOI - PMC - PubMed

[4] Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi:10.1056/NEJMoa2100433 - DOI - PMC - PubMed

[5] Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi:10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed

[6] Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. doi:10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed

[7] Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators . Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi:10.1056/NEJMoa2028836 - DOI - PMC - PubMed

[8] Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators . Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333-2344. doi:10.1056/NEJMoa2028836 - DOI - PMC - PubMed

[9] Salvarani C, Dolci G, Massari M, et al. ; RCT-TCZ-COVID-19 Study Group . Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi:10.1001/jamainternmed.2020.6615 - DOI - PMC - PubMed

[10] Salvarani C, Dolci G, Massari M, et al. ; RCT-TCZ-COVID-19 Study Group . Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. doi:10.1001/jamainternmed.2020.6615 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Affiliations

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials